Chew On This: Medical Marijuana MJNA 50% Stake in CanChew

After doubling in price to start the month of May, the stock price of Medical Marijuana, Inc. (OTC PINK: MJNA) has dropped over -50% to 0.042. That’s about to be corrected now that MJNA, a leading cannabis and hemp industry innovator, acquired a 50% interest in CanChew, a cannabinoid (CBD)-based medicine delivery vehicle in the form of chewing gum. Giving new meaning to “Hubba-Bubba”, this chewing gum could provide an even greater revenue stream to their already profitable business model.

Looking for Hot Penny Stocks? Click here and get Alerts on the Best Penny Stocks FREE.

MJNA Stock Chart

The acquisition of CanChew is said to include ownership of the patents and IP of the product giving Medical Marijuana, Inc.  the exclusive global rights to develop, manufacture, market and distribute both THC and non-THC hemp-derived cannabinoid infused chewing gum to medical marijuana consumers. The FDA currently considers non-THC based hemp products to be “food based” and therefore legal without a medical marijuana license.  Whoo-Hoooooo!

Based on its therapeutic potential and federally legal status, Dixie and Medical Marijuana, Inc., estimate the medical cannabinoid market in the U.S. to be well over $30 billion.  The Company intends to begin production of the CBD-based gum, and in states where legally allowed a THC-infused product, within the next 90 days.

CanChew was developed by the Sanammad Foundation through the efforts of Dr. George Anastassov, Dr. Philip A. Van Damme and Lekhram Changoer to provide relief to patients and the symptoms that accompany severe diseases and injuries by helping to:

• Alleviate acute and chronic pain,
• Diminish nausea and vomiting as well as cachexia, which is a syndrome common in cancer patients on chemotherapy that causes loss of appetite and loss of weight and muscle-mass,
• Enhance appetite,
• Improve muscle relaxation, coordination and mobility,
• Diminish xerostomia, and
• Promote fresh breath and maintain oral hygiene

About Cannabinoids

Cannabinoids have had positive effects in clinical trials on neuralgic pain, Multiple Sclerosis and spinal cord injuries, nausea and vomiting from chemotherapy and radiation treatment as well as palliative treatment of various cancers and HIV/AIDS. According to Michael Llamas, President of Medical Marijuana, Inc., cannabinoids are a highly effctive alternative treatment to relieve pain and symptoms of many diseases but these results are maximized when delivered in the form of chewing gum. Not only is CanChew a more socially acceptable option for the patient but it also has a faster onset and higher absorption in comparison to other conventional formulations.

Chronic pain management costs about $100 billion in treatment and lost productivity annually, and it is reported that 70 percent of all cancer patients experience severe and chronic pain, according to the Pain Foundation.

Bottom Line: For all the penny stocks that deal with the controversial subject of Marijuana for therapeutic uses such as CBIS, HEMP and MJNA, only MJNA has reported revenues worth mentioning and bottom line profits. MJNA has the volatility and investor community to be a consistent 20-30% bi-weekly gainer when momentum builds.

Here is your opportunity to subscribe to the most elite penny stock newsletter.

Sign up with your email address now & get ready to make HUGE PROFITS on stocks that RUN.

(We are 100% Anti-Spam and will never rent or sell your information)

Last updated by at .

  Recent Penny Stock News